NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

大腸激躁症 (IBS) 治療的全球市場的預測:2021年∼2028年

Global Irritable Bowel Syndrome Treatment Market Forecast 2021-2028

出版商 Inkwood Research 商品編碼 985554
出版日期 內容資訊 英文 226 Pages
商品交期: 2-3個工作天內
價格
大腸激躁症 (IBS) 治療的全球市場的預測:2021年∼2028年 Global Irritable Bowel Syndrome Treatment Market Forecast 2021-2028
出版日期: 2021年02月01日內容資訊: 英文 226 Pages
簡介

全球大腸激躁症 (IBS) 治療市場,2021年∼2028年預計以7.25%的年複合成長率成長。促進市場成長的要素,是腸胃疾病的盛行率上升,FDA的認證、醫藥品開發數增加,大腸激躁症 (IBS)劇增,老年人口增加等。

本報告提供全球大腸激躁症 (IBS) 治療市場相關調查分析,市場動態,市場分析與預測,各地區分析,主要企業相關的系統性資訊。

目錄

第1章 調查範圍、調查手法

第2章 摘要整理

第3章 市場動態

  • 主要促進因素
  • 主要阻礙因素

第4章 主要分析

  • 波特的五力分析
  • COVID-19對大腸激躁症 (IBS) 治療市場的影響
  • 機會矩陣
  • 業者情勢
  • 主要投資考察

第5章 市場:各類型

  • 腹瀉型 (IBS-D)
  • 便秘型 (IBS-C)
  • 混合型 (IBS-M)

第6章 市場:各產品

  • RIFAXIMIN
  • ELUXADOLINE
  • LINACLOTIDE
  • LUBIPROSTONE
  • 其他

第7章 市場:各流通管道

  • 藥妝店、零售藥局
  • 醫院藥局
  • 線上藥局

第8章 市場:各作用機制

  • 5-HT3拮抗劑
  • GUANYLATE CYCLASE RECEPTOR-C AGONIST
  • CHLORIDE CHANNEL ACTIVATOR
  • 其他

第9章 市場:各劑型

  • 固體
  • 液體

第10章 各地區分析

  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第11章 競爭情形

  • 主要策略的發展
  • 企業簡介
    • ABBOTT LABORATORIES
    • BAUSCH HEALTH COMPANIES INC
    • ALLERGAN PLC
    • ARDELYX INC
    • ASTELLAS PHARMA INC
    • ASTRAZENECA PLC
    • GLAXOSMITHKLINE PLC
    • IRONWOOD PHARMACEUTICALS INC
    • JOHNSON & JOHNSON (MCNEIL CONSUMER HEALTHCARE)
    • LANNETT COMPANY INC
    • NOVARTIS AG
    • SEBELA PHARMACEUTICALS INC
    • SYNTHETIC BIOLOGICS INC
    • TAKEDA PHARMACEUTICAL COMPANY LTD
目錄
Product Code: 36225

KEY FINDINGS

The global irritable bowel syndrome treatment market is predicted to grow with a CAGR of 7.25%, during the forecast period of 2021 to 2028. The market growth is mainly fueled by factors like, the rising prevalence of gastrointestinal ailments, the increasing number of FDA approvals and drug developments, the surging occurrence of irritable bowel syndrome, and the growing geriatric population.

MARKET INSIGHTS

Irritable bowel syndrome is characterized as a gastrointestinal disorder of the gut, identified by colon muscle contraction. It primarily affects the large intestine. The condition is linked with the malfunction of the bowel and is predominantly widespread across the elderly population. Constipation, diarrhea, alteration, and discomfort in bowel function, abdominal pain, and bloating, are among the common symptoms of irritable bowel syndrome.

The rising number of FDA approvals, in addition to drug development activities, is expected to augment the global irritable bowel syndrome treatment market growth, during the forecast years. Moreover, the majority of new as well as established players are manufacturing drugs for the condition. As a result, this factor is likely to elevate the availability of the required medicines in the market. For instance, Ardelyx, Inc received the FDA approval in 2019, for its Ibsrela (tenapanor), to treat irritable bowel syndrome with constipation (IBS-C), in adults.

REGIONAL INSIGHTS

The global irritable bowel syndrome treatment market growth is evaluated by assessing North America, Europe, the Asia Pacific, and the rest of the world. The Asia Pacific is set to be the fastest-growing region over the forecast period. The market growth is accredited to improvements across the healthcare infrastructure, the growing number of hospitals equipped with advanced medical facilities, the surging healthcare reforms, and the augmenting research and development sector.

COMPETITIVE INSIGHTS

Some of the leading companies operating in the market are, Allergan PLC, GlaxoSmithKline PLC, Allergan PLC, Novartis AG, AstraZeneca PLC, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. KEY DRIVERS
    • 3.1.1. RISE IN THE INCIDENCE OF GASTROINTESTINAL AILMENTS
    • 3.1.2. GROWING NUMBER OF DRUG DEVELOPMENTS AND FDA APPROVALS
    • 3.1.3. SURGING OCCURENCE OF IRRITABLE BOWEL SYNDROME
    • 3.1.4. INCREASING GERIATRIC POPULATION
  • 3.2. KEY RESTRAINTS
    • 3.2.1. HIGH COST OF DRUGS
    • 3.2.2. LACK OF SKILLED PROFESSIONALS IN DEVELOPING ECONOMIES
    • 3.2.3. LIMITED TREATMENT OPTIONS

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCES ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. IMPACT OF COVID-19 ON IRRITABLE BOWEL SYNDROME TREATMENT MARKET
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE
  • 4.5. KEY INVESTMENT INSIGHTS

5. MARKET BY TYPE

  • 5.1. IBS WITH DIARRHEA
  • 5.2. IBS WITH CONSTIPATION
  • 5.3. MIXED IBS

6. MARKET BY PRODUCT

  • 6.1. RIFAXIMIN
  • 6.2. ELUXADOLINE
  • 6.3. LINACLOTIDE
  • 6.4. LUBIPROSTONE
  • 6.5. OTHER PRODUCTS

7. MARKET BY DISTRIBUTION CHANNEL

  • 7.1. DRUG STORES AND RETAIL PHARMACIES
  • 7.2. HOSPITALS' PHARMACIES
  • 7.3. ONLINE PHARMACIES

8. MARKET BY MECHANISM OF ACTION

  • 8.1. 5HT3 ANTAGONIST
  • 8.2. GUANYLATE CYCLASE RECEPTOR-C AGONIST
  • 8.3. CHLORIDE CHANNEL ACTIVATOR
  • 8.4. OTHER MECHANISM OF ACTIONS

9. MARKET BY DOSAGE

  • 9.1. SOLID
  • 9.2. LIQUID

10. GEOGRAPHICAL ANALYSIS

  • 10.1. NORTH AMERICA
    • 10.1.1. MARKET SIZE & ESTIMATES
    • 10.1.2. KEY GROWTH ENABLERS
    • 10.1.3. KEY CHALLENGES
    • 10.1.4. KEY PLAYERS
    • 10.1.5. COUNTRY ANALYSIS
      • 10.1.5.1. UNITED STATES
      • 10.1.5.2. CANADA
  • 10.2. EUROPE
    • 10.2.1. MARKET SIZE & ESTIMATES
    • 10.2.2. KEY GROWTH ENABLERS
    • 10.2.3. KEY CHALLENGES
    • 10.2.4. KEY PLAYERS
    • 10.2.5. COUNTRY ANALYSIS
      • 10.2.5.1. GERMANY
      • 10.2.5.2. FRANCE
      • 10.2.5.3. UNITED KINGDOM
      • 10.2.5.4. ITALY
      • 10.2.5.5. RUSSIA
      • 10.2.5.6. BELGIUM
      • 10.2.5.7. POLAND
      • 10.2.5.8. REST OF EUROPE
  • 10.3. ASIA PACIFIC
    • 10.3.1. MARKET SIZE & ESTIMATES
    • 10.3.2. KEY GROWTH ENABLERS
    • 10.3.3. KEY CHALLENGES
    • 10.3.4. KEY PLAYERS
    • 10.3.5. COUNTRY ANALYSIS
      • 10.3.5.1. JAPAN
      • 10.3.5.2. CHINA
      • 10.3.5.3. AUSTRALIA & NEW ZEALAND
      • 10.3.5.4. INDIA
      • 10.3.5.5. SOUTH KOREA
      • 10.3.5.6. THAILAND
      • 10.3.5.7. INDONESIA
      • 10.3.5.8. VIETNAM
      • 10.3.5.9. REST OF ASIA PACIFIC
  • 10.4. REST OF WORLD
    • 10.4.1. MARKET SIZE & ESTIMATES
    • 10.4.2. KEY GROWTH ENABLERS
    • 10.4.3. KEY CHALLENGE
    • 10.4.4. KEY PLAYERS
    • 10.4.5. REGIONAL ANALYSIS
      • 10.4.5.1. LATIN AMERICA
      • 10.4.5.2. MIDDLE EAST & AFRICA

11. COMPETITIVE LANDSCAPE

  • 11.1. KEY STRATEGIC DEVELOPMENTS
    • 11.1.1. MERGER & ACQUISITIONS
    • 11.1.2. PRODUCT LAUNCH & DEVELOPMENTS
    • 11.1.3. PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
    • 11.1.4. BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
  • 11.2. COMPANY PROFILE
    • 11.2.1. ABBOTT LABORATORIES
    • 11.2.2. BAUSCH HEALTH COMPANIES INC
    • 11.2.3. ALLERGAN PLC
    • 11.2.4. ARDELYX INC
    • 11.2.5. ASTELLAS PHARMA INC
    • 11.2.6. ASTRAZENECA PLC
    • 11.2.7. GLAXOSMITHKLINE PLC
    • 11.2.8. IRONWOOD PHARMACEUTICALS INC
    • 11.2.9. JOHNSON & JOHNSON (MCNEIL CONSUMER HEALTHCARE)
    • 11.2.10. LANNETT COMPANY INC
    • 11.2.11. NOVARTIS AG
    • 11.2.12. SEBELA PHARMACEUTICALS INC
    • 11.2.13. SYNTHETIC BIOLOGICS INC
    • 11.2.14. TAKEDA PHARMACEUTICAL COMPANY LTD

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - IRRITABLE BOWEL SYNDROME TREATMENT
  • TABLE 2: NUMBER OF PERSONS AGED 65 YEARS OR OVER BY GEOGRAPHIC REGION, 2019 AND 2050
  • TABLE 3: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 4: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 5: GLOBAL IBS WITH DIARRHEA MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 6: GLOBAL IBS WITH DIARRHEA MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 7: GLOBAL IBS WITH CONSTIPATION MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 8: GLOBAL IBS WITH CONSTIPATION MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 9: GLOBAL MIXED IBS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 10: GLOBAL MIXED IBS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 11: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 12: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 13: GLOBAL RIFAXIMIN MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 14: GLOBAL RIFAXIMIN MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 15: GLOBAL ELUXADOLINE MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 16: GLOBAL ELUXADOLINE MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 17: GLOBAL LINACLOTIDE MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 18: GLOBAL LINACLOTIDE MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 19: GLOBAL LUBIPROSTONE MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 20: GLOBAL LUBIPROSTONE MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 21: GLOBAL OTHER PRODUCTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 22: GLOBAL OTHER PRODUCTS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 23: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 24: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 25: GLOBAL DRUG STORES AND RETAIL PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 26: GLOBAL DRUG STORES AND RETAIL PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 27: GLOBAL HOSPITALS' PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 28: GLOBAL HOSPITALS' PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 29: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 30: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 31: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 32: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 33: GLOBAL 5HT3 ANTAGONIST MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 34: GLOBAL 5HT3 ANTAGONIST MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 35: GLOBAL GUANYLATE CYCLASE RECEPTOR-C AGONIST MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 36: GLOBAL GUANYLATE CYCLASE RECEPTOR-C AGONIST MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 37: GLOBAL CHLORIDE CHANNEL ACTIVATOR MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 38: GLOBAL CHLORIDE CHANNEL ACTIVATOR MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 39: GLOBAL OTHER MECHANISM OF ACTIONS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 40: GLOBAL OTHER MECHANISM OF ACTIONS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 41: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 42: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 43: GLOBAL SOLID MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 44: GLOBAL SOLID MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 45: GLOBAL LIQUID MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 46: GLOBAL LIQUID MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 47: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 48: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 49: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 50: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 51: LEADING PLAYERS OPERATING IN NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET
  • TABLE 52: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 53: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 54: LEADING PLAYERS OPERATING IN EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET
  • TABLE 55: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 56: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 57: LEADING PLAYERS OPERATING IN ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET
  • TABLE 58: REST OF WORLD IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 59: REST OF WORLD IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 60: LEADING PLAYERS OPERATING IN REST OF WORLD IRRITABLE BOWEL SYNDROME TREATMENT MARKET

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: KEY INVESTMENT INSIGHTS
  • FIGURE 5: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, IN 2020
  • FIGURE 6: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY IBS WITH DIARRHEA, 2021-2028 (IN $ MILLION)
  • FIGURE 7: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY IBS WITH CONSTIPATION, 2021-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MIXED IBS, 2021-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, IN 2020
  • FIGURE 10: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY RIFAXIMIN, 2021-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY ELUXADOLINE, 2021-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LINACLOTIDE, 2021-2028 (IN $ MILLION)
  • FIGURE 13: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LUBIPROSTONE, 2021-2028 (IN $ MILLION)
  • FIGURE 14: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY OTHER PRODUCTS, 2021-2028 (IN $ MILLION)
  • FIGURE 15: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, IN 2020
  • FIGURE 16: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DRUG STORES AND RETAIL PHARMACIES, 2021-2028 (IN $ MILLION)
  • FIGURE 17: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY HOSPITALS' PHARMACIES, 2021-2028 (IN $ MILLION)
  • FIGURE 18: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY ONLINE PHARMACIES, 2021-2028 (IN $ MILLION)
  • FIGURE 19: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, IN 2020
  • FIGURE 20: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY 5HT3 ANTAGONIST, 2021-2028 (IN $ MILLION)
  • FIGURE 21: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY GUANYLATE CYCLASE RECEPTOR-C AGONIST, 2021-2028 (IN $ MILLION)
  • FIGURE 22: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY CHLORIDE CHANNEL ACTIVATOR, 2021-2028 (IN $ MILLION)
  • FIGURE 23: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY OTHER MECHANISM OF ACTIONS, 2021-2028 (IN $ MILLION)
  • FIGURE 24: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, IN 2020
  • FIGURE 25: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY SOLID, 2021-2028 (IN $ MILLION)
  • FIGURE 26: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LIQUID, 2021-2028 (IN $ MILLION)
  • FIGURE 27: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 28: UNITED STATES IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 29: CANADA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 30: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 31: GERMANY IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 32: FRANCE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 33: UNITED KINGDOM IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 34: ITALY IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 35: RUSSIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 36: BELGIUM IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 37: POLAND IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 38: REST OF EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 39: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 40: JAPAN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 41: CHINA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 42: AUSTRALIA & NEW ZEALAND IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 43: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 44: SOUTH KOREA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 45: THAILAND IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 46: INDONESIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 47: VIETNAM IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 48: REST OF ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 49: REST OF WORLD IRRITABLE BOWEL SYNDROME TREATMENT MARKET, REGIONAL OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 50: LATIN AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 51: MIDDLE EAST & AFRICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)